VISUAL FUNCTION RESPONSE TO OCRIPLASMIN FOR THE TREATMENT OF VITREOMACULAR TRACTION AND MACULAR HOLE

被引：0
|
作者：
Jackson, T. [1 ]
Verstraeten, T. [2 ]
Duchateau, L. [3 ]
Lescrauwaet, B. [4 ]
机构：
[1] Kings Coll Hosp London, London, England
[2] P95, Leuven, Belgium
[3] Univ Ghent, Ghent, Belgium
[4] Xintera Ltd, London, England
来源：
VALUE IN HEALTH | 2014年 / 17卷 / 03期
关键词：
D O I：
10.1016/j.jval.2014.03.1681
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PSS34
引用
收藏
页码：A289 / A289
页数：1
相关论文
共 50 条
  • [21] EFFECT OF FUNDING SOURCE ON REPORTING BIAS IN STUDIES OF OCRIPLASMIN THERAPY FOR VITREOMACULAR TRACTION AND MACULAR HOLE
    Hubschman, Sasha
    Venincasa, Michael J.
    Kuriyan, Ajay
    Sridhar, Jayanth
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2019, 60 (09)
  • [22] PATIENT-REPORTED VISUAL FUNCTION FROM THE OCRIPLASMIN FOR TREATMENT FOR SYMPTOMATIC VITREOMACULAR ADHESION, INCLUDING MACULAR HOLE (OASIS) STUDY
    Mein, Calvin
    Dugel, Pravin U.
    Feiner, Leonard
    Drenser, Kim
    Miller, Daniel
    Benz, Matthew
    Meunier, Esmeralda
    Moro, Lionel
    Fineman, Mitchell S.
    RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES, 2020, 40 (07): : 1331 - 1338
  • [23] Initial experience with ocriplasmin in the treatment of vitreomacular traction
    Botto de Barros Garcia, Jose Mauricio
    Cruvinel Isaac, David Leonardo
    Avila, Marcos
    ARQUIVOS BRASILEIROS DE OFTALMOLOGIA, 2016, 79 (02) : 85 - 87
  • [24] Intravitreal ocriplasmin: A breakthrough in the treatment of vitreomacular traction?
    Mec-Slomska, Anna E.
    Adamiec-Mroczek, Joanna
    Kuzmicz, Ewa
    Misiuk-Hojlo, Marta
    ADVANCES IN CLINICAL AND EXPERIMENTAL MEDICINE, 2017, 26 (03): : 527 - 531
  • [25] Jetrea® (Ocriplasmin) as a treatment option for symptomatic vitreomacular traction with or without macular hole (≤400 μm) in comparison to transconjunctival vitrectomy
    Maier, Mathias M.
    Abraham, Sophia
    Frank, Christiane
    Feucht, Nikolaus
    Lohmann, Chris P.
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2015, 56 (07)
  • [26] Macular Hole and vitreomacular Traction (2022)
    不详
    OPHTHALMOLOGIE, 2023, 120 : S70 - S70
  • [27] Cost effectiveness of ocriplasmin for the treatment of vitreomacular traction, including when associated with macular hole ≤ 400 μm: A Swedish perspective
    Gairy, Kerry
    Bennison, Craig
    Thurston, Stephanie
    Lescrauwaet, Benedicte
    Aaberg, Jorgen
    ACTA OPHTHALMOLOGICA, 2014, 92 : 21 - 21
  • [28] Macular Hole and vitreomacular Traction (2022)
    不详
    OPHTHALMOLOGIE, 2023, 120 : S70 - S70
  • [29] Anatomical and visual outcomes following ocriplasmin treatment for symptomatic vitreomacular traction syndrome
    Singh, Rishi P.
    Li, Ang
    Bedi, Rumneek
    Srivastava, Sunil
    Sears, Jonathan E.
    Ehlers, Justis P.
    Schachat, Andrew P.
    Kaiser, Peter K.
    BRITISH JOURNAL OF OPHTHALMOLOGY, 2014, 98 (03) : 356 - 360
  • [30] Early vitreomacular separation with delayed macular hole closure after ocriplasmin treatment
    Liang, I-Chia
    Wang, Kai
    Chien, Hsiang-Wen
    Lin, Szu-Yuan
    INDIAN JOURNAL OF OPHTHALMOLOGY, 2016, 64 (03) : 222 - 224
12345